Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells

Flavio Arienti, Filiberto Belli, Filomena Napolitano, Josep Sulé-Suso, Arabella Mazzocchi, Gian Francesco Gallino, Alessandro Cattelan, Cristina Sanantonio, Licia Rivoltini, Cecilia Melani, Mario Paolo Colombo, Natale Cascinelli, Michele Maio, Giorgio Parmiani

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

A human melanoma line genetically modified to release interleukin 4 (IL- 4) was utilized to immunize advanced melanoma patients in order to elicit or increase a specific anti-melanoma immune response, which may affect distant lesions. Twelve metastatic melanoma patients were injected subcutaneously at least three times with 5 x 107 IL-4 gene-transduced and irradiated allogeneic melanoma cells per dose. Both systemic and local toxicities were mild, consisting of transient fever and erythema, swelling, and induration at the vaccination site. Two mixed but not complete or partial clinical responses were recorded. To assess the immune response of vaccinated patients, both serological and cell-mediated activities were evaluated. Antibodies to alloantigens could be detected in 2 of 11 patients tested. Mixed tumor-lymphocyte cultures were performed, utilizing autologous and allogeneic HLA-A2-matched melanoma lines as simulators and targets. A significant increase in IFN-γ release was detected in 7 of 11 cases when postvaccination lymphocytes were stimulated by the untransduced allomelanoma cells. However, induction of a specific recognition of autologous melanoma cells by PBLs was obtained after vaccination in only one of six cases studied. This response involved the melanoma peptide Melan-A/MART-127-35 that was recognized in an HLA-A2-restricted fashion. These results indicate that vaccination with allogeneic melanoma cells releasing IL-4 locally can expand a T cell response against antigen(s) of autologous, untransduced tumor, although in a minority of patients.

Original languageEnglish
Pages (from-to)2907-2916
Number of pages10
JournalHuman Gene Therapy
Volume10
Issue number18
DOIs
Publication statusPublished - Dec 10 1999

Fingerprint

Interleukin-4
Melanoma
Vaccination
Genes
HLA-A2 Antigen
MART-1 Antigen
Lymphocytes
Isoantigens
Autoantigens
Erythema
Neoplasms
Fever
T-Lymphocytes
Peptides
Antibodies

ASJC Scopus subject areas

  • Genetics

Cite this

Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. / Arienti, Flavio; Belli, Filiberto; Napolitano, Filomena; Sulé-Suso, Josep; Mazzocchi, Arabella; Gallino, Gian Francesco; Cattelan, Alessandro; Sanantonio, Cristina; Rivoltini, Licia; Melani, Cecilia; Colombo, Mario Paolo; Cascinelli, Natale; Maio, Michele; Parmiani, Giorgio.

In: Human Gene Therapy, Vol. 10, No. 18, 10.12.1999, p. 2907-2916.

Research output: Contribution to journalArticle

Arienti, Flavio ; Belli, Filiberto ; Napolitano, Filomena ; Sulé-Suso, Josep ; Mazzocchi, Arabella ; Gallino, Gian Francesco ; Cattelan, Alessandro ; Sanantonio, Cristina ; Rivoltini, Licia ; Melani, Cecilia ; Colombo, Mario Paolo ; Cascinelli, Natale ; Maio, Michele ; Parmiani, Giorgio. / Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. In: Human Gene Therapy. 1999 ; Vol. 10, No. 18. pp. 2907-2916.
@article{57fabb49077e44caa4b112dcff14369d,
title = "Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells",
abstract = "A human melanoma line genetically modified to release interleukin 4 (IL- 4) was utilized to immunize advanced melanoma patients in order to elicit or increase a specific anti-melanoma immune response, which may affect distant lesions. Twelve metastatic melanoma patients were injected subcutaneously at least three times with 5 x 107 IL-4 gene-transduced and irradiated allogeneic melanoma cells per dose. Both systemic and local toxicities were mild, consisting of transient fever and erythema, swelling, and induration at the vaccination site. Two mixed but not complete or partial clinical responses were recorded. To assess the immune response of vaccinated patients, both serological and cell-mediated activities were evaluated. Antibodies to alloantigens could be detected in 2 of 11 patients tested. Mixed tumor-lymphocyte cultures were performed, utilizing autologous and allogeneic HLA-A2-matched melanoma lines as simulators and targets. A significant increase in IFN-γ release was detected in 7 of 11 cases when postvaccination lymphocytes were stimulated by the untransduced allomelanoma cells. However, induction of a specific recognition of autologous melanoma cells by PBLs was obtained after vaccination in only one of six cases studied. This response involved the melanoma peptide Melan-A/MART-127-35 that was recognized in an HLA-A2-restricted fashion. These results indicate that vaccination with allogeneic melanoma cells releasing IL-4 locally can expand a T cell response against antigen(s) of autologous, untransduced tumor, although in a minority of patients.",
author = "Flavio Arienti and Filiberto Belli and Filomena Napolitano and Josep Sul{\'e}-Suso and Arabella Mazzocchi and Gallino, {Gian Francesco} and Alessandro Cattelan and Cristina Sanantonio and Licia Rivoltini and Cecilia Melani and Colombo, {Mario Paolo} and Natale Cascinelli and Michele Maio and Giorgio Parmiani",
year = "1999",
month = "12",
day = "10",
doi = "10.1089/10430349950016320",
language = "English",
volume = "10",
pages = "2907--2916",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "18",

}

TY - JOUR

T1 - Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells

AU - Arienti, Flavio

AU - Belli, Filiberto

AU - Napolitano, Filomena

AU - Sulé-Suso, Josep

AU - Mazzocchi, Arabella

AU - Gallino, Gian Francesco

AU - Cattelan, Alessandro

AU - Sanantonio, Cristina

AU - Rivoltini, Licia

AU - Melani, Cecilia

AU - Colombo, Mario Paolo

AU - Cascinelli, Natale

AU - Maio, Michele

AU - Parmiani, Giorgio

PY - 1999/12/10

Y1 - 1999/12/10

N2 - A human melanoma line genetically modified to release interleukin 4 (IL- 4) was utilized to immunize advanced melanoma patients in order to elicit or increase a specific anti-melanoma immune response, which may affect distant lesions. Twelve metastatic melanoma patients were injected subcutaneously at least three times with 5 x 107 IL-4 gene-transduced and irradiated allogeneic melanoma cells per dose. Both systemic and local toxicities were mild, consisting of transient fever and erythema, swelling, and induration at the vaccination site. Two mixed but not complete or partial clinical responses were recorded. To assess the immune response of vaccinated patients, both serological and cell-mediated activities were evaluated. Antibodies to alloantigens could be detected in 2 of 11 patients tested. Mixed tumor-lymphocyte cultures were performed, utilizing autologous and allogeneic HLA-A2-matched melanoma lines as simulators and targets. A significant increase in IFN-γ release was detected in 7 of 11 cases when postvaccination lymphocytes were stimulated by the untransduced allomelanoma cells. However, induction of a specific recognition of autologous melanoma cells by PBLs was obtained after vaccination in only one of six cases studied. This response involved the melanoma peptide Melan-A/MART-127-35 that was recognized in an HLA-A2-restricted fashion. These results indicate that vaccination with allogeneic melanoma cells releasing IL-4 locally can expand a T cell response against antigen(s) of autologous, untransduced tumor, although in a minority of patients.

AB - A human melanoma line genetically modified to release interleukin 4 (IL- 4) was utilized to immunize advanced melanoma patients in order to elicit or increase a specific anti-melanoma immune response, which may affect distant lesions. Twelve metastatic melanoma patients were injected subcutaneously at least three times with 5 x 107 IL-4 gene-transduced and irradiated allogeneic melanoma cells per dose. Both systemic and local toxicities were mild, consisting of transient fever and erythema, swelling, and induration at the vaccination site. Two mixed but not complete or partial clinical responses were recorded. To assess the immune response of vaccinated patients, both serological and cell-mediated activities were evaluated. Antibodies to alloantigens could be detected in 2 of 11 patients tested. Mixed tumor-lymphocyte cultures were performed, utilizing autologous and allogeneic HLA-A2-matched melanoma lines as simulators and targets. A significant increase in IFN-γ release was detected in 7 of 11 cases when postvaccination lymphocytes were stimulated by the untransduced allomelanoma cells. However, induction of a specific recognition of autologous melanoma cells by PBLs was obtained after vaccination in only one of six cases studied. This response involved the melanoma peptide Melan-A/MART-127-35 that was recognized in an HLA-A2-restricted fashion. These results indicate that vaccination with allogeneic melanoma cells releasing IL-4 locally can expand a T cell response against antigen(s) of autologous, untransduced tumor, although in a minority of patients.

UR - http://www.scopus.com/inward/record.url?scp=0033544933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033544933&partnerID=8YFLogxK

U2 - 10.1089/10430349950016320

DO - 10.1089/10430349950016320

M3 - Article

C2 - 10609652

AN - SCOPUS:0033544933

VL - 10

SP - 2907

EP - 2916

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 18

ER -